Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN632 Monotherapy in CD123-positive AML and Other Hematologic Malignancies
NCT03386513Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 2 trial of pivekimab sunirine in acute myeloid leukemia (AML), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute lymphoblastic leukemia (ALL), hematologic malignancy, sponsored by AbbVie Inc.. Started Jan 2018; status: active, not recruiting.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)acute lymphoblastic leukemia (ALL)hematologic malignancy
Beyond the preview
Go deeper on NCT03386513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386513.